# Single-dose Pharmacokinetics and Safety of Oral Lofexidine in Renally-Impaired Subjects

> **NCT02313103** · PHASE1 · COMPLETED · sponsor: **USWM, LLC (dba US WorldMeds)** · enrollment: 16 (actual)

## Conditions studied

- Renally Impaired Subjects

## Interventions

- **DRUG:** lofexidine HCl

## Key facts

- **NCT ID:** NCT02313103
- **Lead sponsor:** USWM, LLC (dba US WorldMeds)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02313103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02313103, "Single-dose Pharmacokinetics and Safety of Oral Lofexidine in Renally-Impaired Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02313103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*